Skip to contentB
BridgeBio Pharma, Inc.
B
BBIOBridgeBio Pharma, Inc. Q2 2022 · 10-Q
Revenue$73.75M$73.75M+36.5% vs Q2 2021 Net Income-$2.56M-$2.56MN/M vs Q2 2021 EPS Diluted-$0.07-$0.07N/M vs Q2 2021 Operating Income-$80,176,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BridgeBio Pharma, Inc. · CIK 1743881 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$32,855,000N/M Margins · derivedOperating margin-108.7%+65.3 pt vs Q2 2021
Net margin-3.5%+185.5 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 4, 2022 · 35 d after period end